Candesartan Cilexetil EP Impurity A

Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR
Bhanu Ramana,∗, Brajesh A. Sharmaa,b, Ganesh Mahale b, Dharmendra Singhb, Ashok Kumar
Journal of Pharmaceutical and Biomedical Analysis 56 (2011) 256–263
 
Synergistic suppression of tumor angiogenesis by codelivering of VEGF targeted siRNA and candesartan mediated by functionalized carbon nanovectors
Xuefang Ding, Yujie Su, Cheng Wang, Fangrong Zhang, Kerong Chen, Yu Wang, Min Li, and Wei Wang
ACS Appl. Mater. Interfaces 2017, 9, 28, 23353–23369
 
Identification, Isolation, and Characterization of Five Potential Degradation Impurities in Candesartan Cilexetil Tablets
Arivozhi Mohan1,&, S. Shanmugavel1 , Ajay Goyal1 , B. R. Venkataraman2 , D. Saravanan
Chromatographia volume 69, pages1211–1220(2009)

Candesartan Cilexetil EP Impurity A is chemically Ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (as per EP) ; Ethyl 1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-ethoxybenzimidazole-7-carboxylate (as per USP). It is also known as Candesartan Cilexetil USP Related Compound A ; Candesartan Ethyl Ester. Candesartan Cilexetil EP Impurity A is supplied with detailed characterization data compliant with regulatory guideline. Candesartan Cilexetil EP Impurity A can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Candesartan.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.